Kappa opioid receptor activation increases thermogenic energy expenditure which drives increased feeding

Aaron L Cone  
*Washington University School of Medicine in St. Louis*

Kenny K Wu  
*Washington University School of Medicine in St. Louis*

Alexxai V Kravitz  
*Washington University School of Medicine in St. Louis*

Aaron J Norris  
*Washington University School of Medicine in St. Louis*

Follow this and additional works at: [https://digitalcommons.wustl.edu/oa_4](https://digitalcommons.wustl.edu/oa_4)

Part of the *Medicine and Health Sciences Commons*

Please let us know how this document benefits you.

**Recommended Citation**

Cone, Aaron L; Wu, Kenny K; Kravitz, Alexxai V; and Norris, Aaron J, "Kappa opioid receptor activation increases thermogenic energy expenditure which drives increased feeding." *iScience*. 26, 7. 107241 (2023).  
[https://digitalcommons.wustl.edu/oa_4/2415](https://digitalcommons.wustl.edu/oa_4/2415)

This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Kappa opioid receptor activation increases thermogenic energy expenditure which drives increased feeding

**Highlights**
- Activation of kappa opioid receptors (KOR) in the CNS increases thermogenesis
- KOR mediate activation of BAT requires Ucp1 and beta-3 adrenergic receptors
- KOR induced increased feeding requires increased BAT thermogenesis
- Chronic high-fat diet reversibly disrupts KOR-induced thermogenesis
Kappa opioid receptor activation increases thermogenic energy expenditure which drives increased feeding

Aaron L. Cone, Kenny K. Wu, Alexxai V. Kravitz, and Aaron J. Norris

SUMMARY

Opioid receptors, including the kappa opioid receptor (KOR), exert control over thermoregulation and feeding behavior. Notably, activation of KOR stimulates food intake, leading to postulation that KOR signaling plays a central role in managing energy intake. KOR has also been proposed as a target for treating obesity. Herein, we report studies examining how roles for KOR signaling in regulating thermogenesis, feeding, and energy balance may be interrelated using pharmacological interventions, genetic tools, quantitative thermal imaging, and metabolic profiling. Our findings demonstrate that activation of KOR in the central nervous system causes increased energy expenditure via brown adipose tissue activation. Importantly, pharmacologic, or genetic inhibition of brown adipose tissue thermogenesis prevented the elevated food intake triggered by KOR activation. Furthermore, our data reveal that KOR-mediated thermogenesis elevation is reversibly disrupted by chronic high-fat diet, implicating KOR signaling as a potential mediator in high-fat diet-induced weight gain.

INTRODUCTION

Energy balance—maintaining energy intake to meet expenditures—is critical to survival and health. For endotherms, such as humans and mice, maintenance of body temperature can represent a substantial energy demand. Brown adipose tissue (BAT) is important for thermal homeostasis in mice, as it generates heat through uncoupled respiration. BAT is present in adult humans and is increasingly understood as important in promoting health. Uncoupled protein 1 (Ucp1), encoded by the gene Ucp1, is a mitochondrial protein responsible for BAT thermogenesis. Neural networks in the central nervous system (CNS) that regulate sympathetic nervous system activity are key modulators of BAT thermogenesis, since they coordinate the release of norepinephrine onto BAT and lead to increased thermogenesis. Neural circuits integrate energy consumption and regulate feeding behavior. For example, neurons in the arcuate nucleus that promote feeding are activated in response to cold-induced energy demand to increase food intake, linking energy expended to maintain body temperature to energy intake.

Opioid systems modulate body temperature and stimulate feeding behaviors, supporting roles for these signaling pathways as key regulators of energy balance. Like other canonical opioid receptors, the kappa opioid receptor (KOR) is a seven transmembrane domain G protein-coupled receptor that modulates metabolism and thermal regulation. KOR also mediates responses to caloric challenge; specifically, targeted genetic deletion of KOR mitigates diet-induced obesity and KOR antagonism in the setting of caloric restriction promotes weight loss. Conversely, activation of the kappa opioid system increases food intake. The compound U50,488H (U50), a selective kappa opioid agonist, causes hyperthermia and increases oxygen consumption, suggesting that the kappa opioid system plays a role in energy expenditure as well as intake. Recent studies in rats suggest that KOR signaling is altered by diet-induced obesity leading to inhibition of BAT activation. Here, we examined how roles for KOR signaling in regulating thermogenesis, feeding, and energy balance may be interrelated.

In this study, we used quantitative thermal imaging, indirect calorimetry, and home cage feeding devices (FED3) to monitor food intake and investigate the roles of KOR activation in regulating thermogenesis, energy use, and feeding. We also examined the impact of diet-induced obesity on the thermogenic effects of KOR activation. We found that KOR activation in the CNS induces hyperthermia by increasing BAT...
To test if the observed effects of U50 were mediated specifically through KOR, we carried out experiments using mice (Oprk1-/-) harboring a targeted disruption of Oprk1, the gene encoding KOR (Figures 1E–1H). We injected Oprk1-/- mice (n = 5; 3 males and 2 females) with U50 or saline and obtained quantitative thermal imaging videos (see image examples in Figure 1E). Analysis revealed no significant effects of U50 injection on BAT, eye, or tail temperature compared to injection of saline (Figures 1F–1H). There were no significant differences in temperatures obtained from implanted transponders (Figure 1 and S1A). These results demonstrate U50 effects on body temperatures are mediated specifically through KOR.

We examined the effects of multiple doses of U50 on body temperatures (Figures 1 and S1B–S1D). We injected wild-type mice (n = 7; 4 males and 3 females) with i.p. saline or with 2, 5, or 10 mg/kg of U50 in a pseudorandomized order with at least 24 h between doses. We obtained quantitative thermal imaging of mice for each injection, and video analysis showed that all U50 doses tested increased BAT, eye, and tail temperatures (Figures 1 and S1B). The 5 mg/kg dose evoked the largest increase in BAT temperature, and mean BAT temperatures at 35 to 65 min were significantly (p < 0.001, paired t-test) different from the 2 mg/kg dose, but not the 10 mg/kg dose (Figures 1 and S1B). The 10 mg/kg dose produced the largest increase in mean eye temperatures, with a more rapid rise than seen following the 5 mg/kg dose.
Compared to the 5 mg/kg dose, the 10 mg/kg dose resulted in significantly higher mean temperatures at the 45-min mark (p = 0.007). The effect of 10 mg/kg dose was also longer lasting than 2 mg/kg dose (Figures 1 and S1C). Similar trends were observed for tail temperatures, although the elevated temperatures evoked by the 10 mg/kg dose were longer lasting than those following 2 or 5 mg/kg U50 (Figures 1 and S1D).

**KOR activation in the central nervous system drives increased BAT thermogenesis**

KOR is expressed in the CNS and peripheral tissues, thus we examined whether KOR activation in the central or peripheral nervous system underlies the effects of U50 on body temperatures. In this set of

---

**Figure 1. KOR activation evokes BAT thermogenesis, hyperthermia, and tail vasodilation**

(A) Quantitative thermal images of BAT, eye, and tail at 0, 50, 70, and 90 min after i.p. administration of 5 mg/kg U50, 488H (U50) in wild-type mice.

(B–D) Quantified data for eye, BAT, and tail temperatures after pretreatment with saline or 10 mg/kg naltrexone hydrochloride i.p., then 30 min later 5 mg/kg U50 (n = 10).

(E) Thermal images of eye, BAT, and tail at 0, 50, 70, and 90 min in **Oprk1**/−/− animals after administration of 5 mg/kg U50 i.p.

(F–H) Quantified thermal imaging of eye, BAT, and tail in **Oprk1**/−/− animals. All data are presented as mean ± SEM (n = 5).

Compared to the 5 mg/kg dose, the 10 mg/kg dose resulted in significantly higher mean temperatures at the 45-min mark (p = 0.007). The effect of 10 mg/kg dose was also longer lasting than 2 mg/kg dose (Figures 1 and S1C). Similar trends were observed for tail temperatures, although the elevated temperatures evoked by the 10 mg/kg dose were longer lasting than those following 2 or 5 mg/kg U50 (Figures 1 and S1D).
experiments, we administered (i) peripherally restricted opioid receptor antagonist naloxone methiodide (NLXM), (ii) intracerebroventricularly (i.c.v) administered selective KOR receptor antagonist norbinaltorphimine (norBNI) to block KOR in the CNS, or (iii) saline followed by systemic administration of U50 (Figure 2).37–39 We obtained thermal imaging from mice (n = 7; 4 males and 3 females) and all mice were examined in each condition. Analysis revealed that treatment with NLXM had a minimal effect on U50-induced changes in BAT, eye, and tail temperatures following injection of U50. In contrast, pretreatment with i.c.v. norBNI blocked elevation of BAT, eye, and tail temperatures following systemic administration of U50 (Figures 2D and 2E). Additional analysis showed that pretreatment with NLXM resulted in significantly (p < 0.05, paired t-test) lower mean BAT temperatures only at 85 to 100 min time points compared to saline. Administration of norBNI i.c.v. blocked the elevation in mean BAT temperatures with significantly (p < 0.005, paired t-test) lower values at 35 to 120 min time points. Pretreatment with NLXM blunted the increase in eye temperature slightly, with significant (p < 0.05, paired t-test) differences in mean values noted only at later time points of 70, 75, 85, and 90 min when compared to U50 (Figure 2E). Changes in tail temperature were also blocked by norBNI with significantly (p < 0.05, paired t-test) lower mean values from 35- through 100-min time points compared to saline pretreatment; in contrast, NLXM pretreatment did not significantly alter tail temperatures, except at the 80-min time point (p = 0.025). Taken together, these data indicate that KOR activation in the CNS, and not in the periphery, underlines activation of BAT and resultant hyperthermia.

**KOR activation induces a hypermetabolic state**

To examine if the KOR-evoked increase in thermogenesis is accompanied by changes in metabolism, we used indirect calorimetry to quantify changes in metabolic activity. To minimize possible confounds due to
suppression of locomotor activity, we performed experiments at 10 a.m., a period in the early portion of the light phase when mice show increased sleep and decreased locomotion. We injected mice (n = 13; 8 males and 5 females) i.p. with U50 (5 mg/kg) or saline at 10 a.m. following 3 days of habituation to home changes in a metabolic screening platform. Mice received control or U50 injections 48 h apart. Half of the mice received U50 first. Analysis of data from indirect calorimetry revealed an increase in energy use following U50 administration but not saline (Figure 3A) that had a similar duration as the elevation observed in BAT temperatures (Figure 1). Energy use returned to baseline following a similar time course as normalization of BAT temperatures, approximately 90 min after U50 but not saline. Activity measured by infrared beam breaks for the same period was not increased following U50 compared to saline. Over the same time frame, RER showed normal circadian oscillation with slight downward trend immediately following U50 administration with delayed rapid rise. Cumulative food intake based on decreasing weight of food in the home cage shows increased feeding following U50 compared to saline. Data are presented as mean ± SEM (n = 13).

Figure 3. Activation of KOR leads to a hypermetabolic state
Metabolic phenotyping data including gas exchange, activity, and food intake were acquired. Saline (black) or 5 mg/kg US0 (red) i.p. was administered at 10:00 a.m. on separate days. (A) Calculated energy expenditure from 08:00 through 21:00 for wild-type mice given saline or US0 at 10:00 showing a spike in energy use approximately 90 min after US0 but not saline. (B) Activity measured by infrared beam breaks for the same period was not increased following US0 compared to saline. (C) Over the same time frame, RER showed normal circadian oscillation with slight downward trend immediately following US0 administration with delayed rapid rise. (D) Cumulative food intake based on decreasing weight of food in the home cage shows increased feeding following US0 compared to saline. Data are presented as mean ± SEM (n = 13).
that KOR mediated activation of BAT relies on negligible effects on eye and BAT temperatures (Figures 4, S1A, and S1B). Together, these data indicate SR59230A was given alone, compared with saline (Figures 4 and S1C). In contrast, SR59230A alone has also observed significant (p < 0.05, paired t-test) differences in mean tail temperature at 5 to 120 min when compared to saline alone (Figure 4D–4F). Ucp1 is required for BAT thermogenesis. 8

The change in tail temperatures persisted when SR59230A and U50 were co-administered (Figure 4C). We selected 1300 on saline injection days as a comparator time point because this time point was temporally sufficiently removed from the injections and levels for energy expenditure and activity were similar to time just prior to injections at 1000. Further analyses using linear regression revealed that the increased energy expenditure due to U50 was poorly correlated (R² = 0.17) with changes in activity and that time-of-day dependent change in energy expenditure was correlated with increased physical activity (R² = 0.42) (Figures S2C–S2F). Consistent with prior studies showing U50 suppressed locomotor behavior, we did not find an increase in physical activity following U50 and increased energy expenditure was not explained by physical activity.34,45

**β3 adrenoreceptor activation is required for KOR mediated elevation in BAT thermogenesis**

Activation of β3-AR on adipocytes is a key pathway for promoting BAT thermogenesis.42,46 To examine if the KOR induced increase in BAT thermogenesis was dependent on β3-AR receptor activation, we co-administered a selective β3-AR antagonist, SR59230A (10 mg/kg i.p.), with U50, and saline with U50 to mice (n = 8; 5 males and 3 females) and obtained quantitative thermal imaging (Figure 4). Activation of 3-AR antagonist, SR59230A (10 mg/kg i.p.), with U50, and saline with U50 to mice. Wild-type mice (n = 15; 9 males and 6 females) were injected with SR59230A and U50, and saline with U50 to mice (n = 8) were injected with SR59230A and saline. In Ucp1−/− mice, small rises in BAT, eye, and tail temperatures were evident after co-administration of SR59230A and U50 when compared to saline alone at the 55, 60, 95, and 100-min time points (Figure 4A). Elevation of eye temperature was prevented by co-administration of SR59230A, and the mean eye temperatures were not significantly different when compared to saline alone (Figure 4B). The change in tail temperatures persisted when SR59230A and U50 were co-administered (Figure 4C). We also observed significant (p < 0.05, paired t-test) differences in mean tail temperature at 5 to 120 min when SR59230A was given alone, compared with saline (Figures 4 and S1C). In contrast, SR59230A alone has negligible effects on eye and BAT temperatures (Figures 4, S1A, and S1B). Together, these data indicate that KOR mediated activation of BAT relies on β3-AR receptor activation.

**Ucp1 is required for KOR mediated elevation of BAT thermogenesis**

We carried out thermal imaging experiments in mice (Ucp1−/−) harboring targeted genetic disruption of Ucp1 (Figures 4D–4F). Ucp1 is required for BAT thermogenesis.5 Ucp1−/− mice (n = 8) were injected with saline and U50. In Ucp1−/− mice, small rises in BAT, eye, and tail temperatures were evident after U50 compared to saline. These data indicate the thermogenic effect of U50 is mediated through BAT and that Ucp1 is required. These results align with data obtained using SR59230A to block β3-AR to indicate KOR activation leads to increased norepinephrine release on BAT to initiate thermogenesis through Ucp1 on mitochondria.

**Increased feeding following KOR activation is driven by thermogenesis**

To examine directly if the increased food intake after KOR activation is driven by the energetic demand of thermogenesis, we used FED3 systems (Figure 5A) to monitor feeding behavior with high temporal resolution and quantitative precision.50 We examined wild type and Ucp1−/− mice. Wild-type mice (n = 15; 9
males and 6 females) were injected with either U50 (5 mg/kg) or saline at 10 a.m. Equal portions of animals received saline or U50 first. Compared to saline, more pellets were taken following U50 injection, indicating increased feeding (Figures 5 B and 5C). We observed a delay between U50 administration and the increase in feeding. This delay temporally corresponded to the time period when BAT temperatures (Figure 1 B) and energy expenditure (Figure 3 A) were elevated. Following a transient rise after U50 treatment, mice removed chow pellets at a similar rate as mice did after saline injection. The increase in feeding following U50 administration resulted in significantly (p = 0.0017, paired t-test) increased pellet consumption over the course of 24 h compared with saline control. This was driven by the acute increase in feeding (Figure 5C). To examine if increased BAT thermogenesis is necessary for the increased intake in food, we co-administered U50 with SR59230A to block β3-AR-induced BAT thermogenesis (Figure 4A). Blocking β3-AR prevented BAT activation and abrogated the increase in feeding induced by U50; the mean pellet counts were nearly identical to amounts observed after saline administration (Figure 4E). SR59230A alone (n = 7) did not significantly alter feeding compared to saline (Figure S3E). These data indicate that β3-AR activation is required to drive the increased feeding evoked by KOR activation. To test directly if thermogenesis is required for the increase in feeding, we carried out similar studies in Ucp1−/− mice (n = 9; 5 males and 4 females), that mount a minimal thermogenic response to U50 injection (Figure 4A). In Ucp1−/− mice, injection of U50 did not produce an increase in feeding (Figure 5D) compared to saline treatment. Taken together, these results show that KOR activation induced feeding in mice fed ad lib is dependent on BAT thermogenesis due to activation of β3-AR.

Chronic high-fat diet reversibly disrupts KOR-regulated BAT thermogenesis

Obesity alters regulation of neurotransmission in the CNS. Additionally, rats fed a high-fat diet exhibit dysregulated KOR signaling, which impairs BAT activation by cold. We investigated if activation of BAT via kappa opioid signaling is altered in obese mice chronically fed a high-fat diet for 20 weeks (n = 8) or 32 weeks (n = 8).
We administered U50 to C57BL/6J mice (n = 8, males) maintained on HFD for 32 weeks (9 months old) or 20 weeks (6 months old) starting at six weeks of age. HFD fed mice had a significantly higher mean weight than lean control mice (n = 8) (9 months old) (Figure 6E). Consistent with our previous experiment (Figure 1), U50 administration to lean (chow fed) mice and mice fed HFD for 20 weeks led to elevation of BAT, tail, and eye temperatures (Figures 6 A–6C). In contrast, following U50 administration mean BAT temperatures in mice fed HFD for 30 weeks were significantly (p < 0.05, unpaired t-test) lower from 15 to 75 min (Figure 6A) compared to lean, and from 10 to 90 min compared to mice fed HFD for 20 weeks. Mean eye temperatures were significantly (p < 0.05) lower from 5 to 120 min (Figure 6 B) in mice fed HFD for 30 weeks compared to lean mice. The eye temperatures in mice fed HFD for 20 weeks was intermediate to both other groups, perhaps reflecting a larger body mass to heat. There was no significant difference between mean tail temperatures of lean and HFD fed mice, but the time course of recovery to baseline differed (Figure 6 C).

We next tested if the disruption of KOR-induced thermogenesis in mice fed HFD for 32 weeks would recover when HFD was removed. Obese HFD fed mice were returned to a normal chow diet. One week after switching diets, their weight decreased significantly (mean weight difference, 4.2 ± 0.5 g, p < 0.0001, paired t-test) lower from 15 to 75 min (Figure 6A) compared to lean, and from 10 to 90 min compared to mice fed HFD for 20 weeks. Mean eye temperatures were significantly (p < 0.05) lower from 5 to 120 min (Figure 6B) in mice fed HFD for 30 weeks compared to lean mice. The eye temperatures in mice fed HFD for 20 weeks was intermediate to both other groups, perhaps reflecting a larger body mass to heat. There was no significant difference between mean tail temperatures of lean and HFD fed mice, but the time course of recovery to baseline differed (Figure 6C).

We next tested if the disruption of KOR-induced thermogenesis in mice fed HFD for 32 weeks would recover when HFD was removed. Obese HFD fed mice were returned to a normal chow diet. One week after switching diets, their weight decreased significantly (mean weight difference, 4.2 ± 0.5 g, p < 0.0001, paired t-test) lower from 15 to 75 min (Figure 6A) compared to lean, and from 10 to 90 min compared to mice fed HFD for 20 weeks. Mean eye temperatures were significantly (p < 0.05) lower from 5 to 120 min (Figure 6B) in mice fed HFD for 30 weeks compared to lean mice. The eye temperatures in mice fed HFD for 20 weeks was intermediate to both other groups, perhaps reflecting a larger body mass to heat. There was no significant difference between mean tail temperatures of lean and HFD fed mice, but the time course of recovery to baseline differed (Figure 6C).

We next tested if the disruption of KOR-induced thermogenesis in mice fed HFD for 32 weeks would recover when HFD was removed. Obese HFD fed mice were returned to a normal chow diet. One week after switching diets, their weight decreased significantly (mean weight difference, 4.2 ± 0.5 g, p < 0.0001, paired t-test) lower from 15 to 75 min (Figure 6A) compared to lean, and from 10 to 90 min compared to mice fed HFD for 20 weeks. Mean eye temperatures were significantly (p < 0.05) lower from 5 to 120 min (Figure 6B) in mice fed HFD for 30 weeks compared to lean mice. The eye temperatures in mice fed HFD for 20 weeks was intermediate to both other groups, perhaps reflecting a larger body mass to heat. There was no significant difference between mean tail temperatures of lean and HFD fed mice, but the time course of recovery to baseline differed (Figure 6C).

We next tested if the disruption of KOR-induced thermogenesis in mice fed HFD for 32 weeks would recover when HFD was removed. Obese HFD fed mice were returned to a normal chow diet. One week after switching diets, their weight decreased significantly (mean weight difference, 4.2 ± 0.5 g, p < 0.0001, paired t-test) lower from 15 to 75 min (Figure 6A) compared to lean, and from 10 to 90 min compared to mice fed HFD for 20 weeks. Mean eye temperatures were significantly (p < 0.05) lower from 5 to 120 min (Figure 6B) in mice fed HFD for 30 weeks compared to lean mice. The eye temperatures in mice fed HFD for 20 weeks was intermediate to both other groups, perhaps reflecting a larger body mass to heat. There was no significant difference between mean tail temperatures of lean and HFD fed mice, but the time course of recovery to baseline differed (Figure 6C).

We next tested if the disruption of KOR-induced thermogenesis in mice fed HFD for 32 weeks would recover when HFD was removed. Obese HFD fed mice were returned to a normal chow diet. One week after switching diets, their weight decreased significantly (mean weight difference, 4.2 ± 0.5 g, p < 0.0001, paired t-test) lower from 15 to 75 min (Figure 6A) compared to lean, and from 10 to 90 min compared to mice fed HFD for 20 weeks. Mean eye temperatures were significantly (p < 0.05) lower from 5 to 120 min (Figure 6B) in mice fed HFD for 30 weeks compared to lean mice. The eye temperatures in mice fed HFD for 20 weeks was intermediate to both other groups, perhaps reflecting a larger body mass to heat. There was no significant difference between mean tail temperatures of lean and HFD fed mice, but the time course of recovery to baseline differed (Figure 6C).
g, p = 0.01, paired t-test (Figure 6E). There were no significant differences in BAT thermogenesis after U50 following two weeks on chow compared to one week. These data suggest that chronic HFD induced obesity suppresses KOR activation evoked thermogenesis in a reversible manner.

**DISCUSSION**

We found KOR activation in the CNS evokes BAT thermogenesis leading to hyperthermia and elevated energy expenditure (Figures 1, 2, and 3). Also, we found KOR activation of BAT thermogenesis was blunted by chronic HFD but improved with removal of HFD. Results showing centrally administered (norBNI) but not peripherally restricted (NLMX) opioid receptor antagonists block the U50 evoked thermogenesis and demonstrate that activation of the kappa opioid system within the CNS promotes BAT thermogenesis. The small effects of NLXM on U50-induced changes in body temperatures (Figure 2) may be due to delayed entrance of the drug or metabolites into the CNS, as has been reported for methylnaltrexone. Because NLMX is an antagonist of multiple opioid receptor types, we cannot exclude a partial dependence on peripheral opioid receptors in mediating effects. The increase in thermogenesis due to KOR activation was dependent on β3-AR (Figure 4), indicating KOR activation leads to release of norepinephrine on BAT. Increased thermogenesis likely accounts for the increased energy expenditure following U50 (Figure 3) because the increased energy expenditure followed a similar temporal course as the elevation in BAT temperature. Further, we found no increase in physical activity after U50 (Figure S2) to explain elevation of energy expenditure. U50 administration also increased feeding, but blocking elevation of BAT thermogenesis prevented the increase in feeding (Figure 5). Our interpretation of these findings is that increased feeding following U50 is driven secondarily by increased energy expended through thermogenesis. These findings indicate that increased energy use is potentially integrated on a timescale of minutes to promote enhanced energy intake. By extension, these findings suggest that promoting weight loss by increasing BAT activity could be confounded by increased hunger and feeding drive. The apparent indirect effect of KOR...
activation on feeding is in contrast to results showing mu opiate receptors enhance feeding by acting on neuronal projections from the dorsal raphe in the nucleus accumbens. Our studies here do not address how KOR signaling can alter consumption of palatable foods or feeding in calorically deprived states.

KOR activation led to rapid increases of tail temperatures, potentially representing compensatory response to promote heat loss. Alternatively, KOR activation lowers blood pressure, and the changes in tail temperature may reflect an alteration of the sympathetic nervous system regulation of blood pressure. These competing effects (thermogenesis vs. heat loss) may account for the paradoxical decrease in body temperature observed in prior studies when high doses of KOR agonist were administered. Our data in KOR−/− mice demonstrate that both elevated BAT activity and tail temperatures are mediated specifically through KOR (Figures 1E–1H). Data from Ucp1−/− mice show minimal changes of tail temperatures following U50 injection (Figure 4F). Ucp1−/− mice have intact KOR signaling, but impaired thermogenic activity. Thus, the lack of increase in tail temperatures in Ucp1−/− mice indicates tail vasodilation after U50 is secondary to the thermogenic effects. The rise in tail temperature is seen when β3-AR antagonist is given alone (Figure S3C) likely represents known off target block of alpha-1 adrenergic receptors, which drive vasoconstriction.

In sum, we report KOR activation in the CNS leads to an increase in BAT thermogenesis and, in the ad-lib fed state, KOR-induced feeding is dependent on elevating BAT thermogenesis. These findings add to evidence that the kappa opioid system can regulate metabolism and energy balance.

Limitations of the study
Several questions raised remain unanswered by the results from this study. The target(s) neural circuits altered by KOR activity to drive thermogenesis remain to be identified. One possible site is the lateral hypothalamus (LH). LH has been implicated in thermal regulation, and blockade of KOR in LH can prevent increased feeding. Another possible site is the preoptic area of the hypothalamus. KOR signaling in the POA is important for regulating BAT activation and is perturbed in diet-induced obese rats. However, activating KOR by dialyzing dynorphin into the POA mildly lowers body temperature and may not be responsible for the net effects. KOR signaling may have differential effects on body temperature and energy use dependent on brain site and context. Context-dependent changes in circuit function might explain why we report a hyperthermic effect of KOR activation in ad libitum-fed mice, while others found that KOR antagonism prevented hypothermia in the context of caloric restriction. A second question that remains open is whether chronic HFD directly disrupts kappa opioid system function or causes dysfunction of BAT thermogenesis. Delineating the potential causal role for KOR signaling in disruption of BAT activation is challenging because HFD can alter both KOR signaling and thermogenesis, thereby limiting our ability to separate the two effects without greater understanding of the underlying mechanisms and neural circuits.

In the studies here, we show that blockade of β3-AR or disruption of UPC1 prevents increased BAT temperatures, but we do not examine cellular mechanisms occurring in BAT due to HFD or KOR activation. We also do not examine potential changes in white adipose tissue in response to activation of KOR.

STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS
  - Mice
- METHOD DETAILS
  - Surgeries
  - Pharmacology
  - Quantitative thermal imaging and body temperature measurements
  - Metabolic phenotyping
  - Quantification of feeding using FED3 devices in the home cage
- QUANTIFICATION AND STATISTICAL ANALYSIS
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2023.107241.

ACKNOWLEDGMENTS
This work was supported by the NIH through 5K08MH119538 to AJN. The work was also supported by P30 DK020579 to the Diabetes Research Core at Washington University. We thank Dr. Jonathan Brestoff lab and Roquibat Giwa for providing the Ucp1−/− mice. Graphical abstract illustration by Jessica Tung and Catie Newsom-Stuart in association with InPrint at Washington University in St. Louis.

AUTHOR CONTRIBUTIONS
A.L.C.: project development, experimental design, animal care, project conception and development, data collection, data archiving, data analysis, manuscript writing. K.K.W.: data collection, data archiving, data analysis. A.V.K.: project conception and development, project development, experimental design. A.J.N.: project development, experimental design, project conception and development, data collection, data archiving, data analysis, manuscript writing, funding acquisition, and supervision.

DECLARATION OF INTERESTS
The authors declare no competing interests.

INCLUSION AND DIVERSITY
We worked to ensure sex balance in the selection of non-human subjects. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location.

Received: January 17, 2023
Revised: May 2, 2023
Accepted: June 26, 2023
Published: June 28, 2023

REFERENCES


STAR METHODS

KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemicals, peptides, and recombinant proteins</td>
<td>Sigma-Aldrich</td>
<td></td>
</tr>
<tr>
<td>Naloxone methiodide (NLXM)</td>
<td>Sigma-Aldrich</td>
<td>Cat# N129</td>
</tr>
<tr>
<td>Naltrexone hydrochloride</td>
<td>Sigma-Aldrich</td>
<td>Cat# N3136</td>
</tr>
<tr>
<td>Norbinaltorphimine (norBNI)</td>
<td>Sigma-Aldrich</td>
<td>Cat# N1771</td>
</tr>
<tr>
<td>SR59230A hydrochloride</td>
<td>hydrochloride</td>
<td>Cat# 1511</td>
</tr>
<tr>
<td>U50,488H (U50)</td>
<td>Sigma-Aldrich</td>
<td>Cat# U111</td>
</tr>
</tbody>
</table>

Experimental models: Organisms/strains

| Mouse: C57BL/6BJ | The Jackson Laboratory | RRID:IMSR_JAX:000664 |
| Mouse: C57BL/6J DIO | The Jackson Laboratory | RRID:IMSR_JAX:380050 |
| Mouse: Oprk1tm1.1(cre)Sros/J | Gift from Sarah Ross, Pitt | RRID:IMSR_JAX:035045 |
| Mouse: B6.129S2-Oprk1tm1Kff/J | Gift from Sarah Ross, Pitt | RRID:IMSR_JAX:007558 |
| Mouse: B6.129-Ucp1tm1Kz/J | Gift from Jonathan Brestoff, WashU | RRID:IMSR_JAX:003124 |

Software and algorithms

| ResearchIR | Teledyne FLIR Systems Inc | N/A |
| FLIR E53 thermal imaging cameras | Teledyne FLIR Systems Inc | Cat# FLIR E53 24' |
| Leica Application Suite Advanced Fluorescence | Leica Microsystems | N/A |
| Wireless IPTT-300 temperature transponders | Bio Medic Data Systems | N/A |
| Phenomaster system | LabMaster System; TSE Systems | N/A |
| FED3 device | Open Ephys | N/A |
| GraphPad Prism | GraphPad Software | Version 9.3.1 |

Other

| High fat diet (HFD) (60 kcal% fat) | Research Diets, Inc | Cat# D12492 |
| Guide Cannula | P1 Technologies | N/A |

RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources should be directed to the lead contact Aaron Norris (Norrisa@wustl.edu).

Materials availability
This study did not generate new unique reagents.

Data and code availability
- All data reported in this paper will be shared by the lead contact upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Mice
All procedures were approved by the Animal Care and Use Committee of Washington University and adhered to NIH guidelines. All animals were maintained, handled, and processed in accordance with
the policies of the Institutional Animal Care and Use Committee (IACUC) at Washington University. Mice were bred at Washington University or obtained from the Jackson Laboratory (Bar Harbor, ME). Male and female C57BL/6J or Oprk1<sup>−/−</sup> mice (20–35 g) older than eight weeks of age were used for experiments. Animals were group-housed at a maximum of five per cage, had ad libitum access to food and water, and were maintained on a 12:12 h light:dark cycle (lights on at 6:00 a.m.). Oprk1<sup>−/−</sup> mice harboring the coding sequence for Cre recombinase in the coding region of in exon 2 in Oprk1, thereby expression of functional KOR, were a gift from Dr. Sara Ross (University of Pittsburgh).<sup>69</sup> Ucp1<sup>−/−</sup> mice were a gift from Dr. Jonathan Brestoff’s lab.

For food intake experiments, male diet-induced obese (50–55 g) or control (30–35 g) C57BL/6J mice were acquired from the Jackson Laboratory at 22 weeks of age. Obese animals were maintained on HFD chow D12492 (60 kcal% fat) (Research Diets, Inc; New Brunswick, NJ), and their age-matched controls were maintained on standard mouse chow. These mice represented mice maintained on HFD for 32 weeks. Mice maintained on HFD for 20 weeks were likewise obtained from Jackson Laboratory prior to testing and maintained on HFD until testing. Female diet-induced obese mice were not available from the Jackson Laboratory.

**METHOD DETAILS**

**Surgeries**

Wireless IPTT-300 temperature transponders (Bio Medic Data Systems; Seaford, DE) and cannula for intraventricular drug administration were implanted in mice anesthetized with 2% isoflurane and maintained in oxygen. The transponder was inserted subdermally rostral to the right hindleg.<sup>34</sup> For implantation of guide cannulas, animals were anesthetized on a stereotaxic frame (adapted from DeVos and Miller 2013<sup>70</sup>), and under sterile conditions a small incision was performed to expose the skull. Next, a 5-mm bit was used to drill a hole into the skull where a single guide cannula (P1 Technologies; Roanoke, VA) was placed in the lateral ventricle at stereotaxic coordinates M/L 0.8, A/P 0.22, D/V 1.7. Then, a head cap was built around the guide cannula for keeping it in place, using dental cement. Subsequently, a cannula dummy was screwed onto the guide cannula for protection of obstruction and 5 mg/kg carprofen was administered i.p. post-operatively. Mice were given a minimum of 7 days to recover from the procedure before starting experiments.

**Pharmacology**

U50,488H (U50) (Sigma U111; MilliporeSigma, Saint Louis, MO), naltrexone hydrochloride (NTX) (Sigma N3136), norbinaltorphimine (norBNI) (Sigma N1771), naloxone methiodide (NLXM) (Sigma N129), and SR59230A hydrochloride (Bio-Techne 1511; Minneapolis, MN) were dissolved in 0.9% saline. Prior thermal imaging experiments, animals were habituated in a clear behavior chamber on a platform.<sup>34</sup> After habituation, animals were injected intraperitoneally (i.p.) with vehicle or antagonist, and 30 min later, vehicle or U50 (2, 5, or 10 mg/kg) was injected i.p. For experiments using intracerebroventricular administration of compounds, animals were similarly habituated. The cannula dummy was unscrewed from the guide cannula and the internal injector cannula was placed inside the guide cannula and screwed on securely. Over the course of 5 min, 5 μL of vehicle or 1 nmol norBNI were infused into the ventricle; after 30 min, 5 mg/kg U50 were administered i.p. NLXM was selected as a peripheral restricted antagonists due to reports that in mice methylnaltrexone is rapidly metabolized to naloxone and crosses the blood brain barrier.<sup>71</sup>

**Quantitative thermal imaging and body temperature measurements**

To measure body temperatures, we used FLIR E53 thermal imaging cameras and IPTT-300 temperature transponders. Quantitative thermal image videos were recorded and subsequently analyzed. Briefly, at 5-min intervals, regions of interest containing BAT, eye, or a point at approximately 1 cm from the base of the tail were identified in the highest temperature. For wireless temperature transponders, a DAS-8027 reader (Bio Medic Data Systems Seaford, DE) was held in close proximity under the behavioral arena and temperature from the implanted transponder was recorded.

**Metabolic phenotyping**

Metabolic phenotyping including indirect calorimetry, activity monitoring, and food consumption was carried out using a Phenomaster system (LabMaster System; TSE Systems, Bad Homburg, Germany).<sup>72</sup> Briefly,
animals were singly housed in metabolic cages in the Phenomaster with ad libitum access to food and water. Food intake was measured by subtracting the weight of uneaten food from the initial food weight. Gases were sampled from each cage for 1 min every 10 min with a flow rate of 27 L/h. Metabolic rate was measured using oxygen consumption (mL/h) and carbon dioxide production (mL/h) which was calculated via comparison of the air from the reference cage that had no animal in it. The RER was calculated by dividing CO₂ production (VCO₂) by O₂ consumption (VO₂). Energy expenditure was converted from the metabolic rate using constants CVO₂ = 3.941 and CVCO₂ = 1.106 and the equation EE = (CVO₂ * VO₂ + CVCO₂ * VCO₂)/1000. Physical activity was obtained by quantification of beam breaks. Activity was sampled at 100 Hz and reported in 10-min summed bins which were consolidated to 30-min bins. Physical activity is reported as total beam breaks for all three axes by the animals in the cage. Animals were habituated for 3 days to Phenomaster housing; on day 4 and day 5, at 10:00 a.m., animals were injected with either saline or 5 mg/kg U50 and the metabolic rate was acquired.

**Quantification of feeding using FED3 devices in the home cage**

We used FED3 devices to monitor feeding of singly housed mice. The FED3 devices were programmed to dispense one 20-mg standard chow pellet at a time, and automatically replaced the pellet after it was taken. Timestamps for each dispensed pellet were recorded. FED3 offered greater precision than the metabolic phenotyping home cages. The FED3 was the only source of food in the cage. Mice were given 3 days to habituate to FED3 feeding prior to experiments. Stable feeding was required before experiments. Mice and functioning of the FEDs were checked daily.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Statistical analysis was carried out using Prism software (GraphPad; San Diego, CA). For comparisons between two sets of time-course data, different Student’s t tests were used. For experiments where the same mice were tested in multiple conditions a paired test was applied, and when different mice were compared an unpaired test was used. For time-course thermal data p values were not corrected for multiple comparisons across time. For comparisons of three or more groups, a one-way ANOVA was used. A repeated measures ANOVA was used for experiments where the same subject was used across multiple conditions. All data are reported as mean ± SEM.